Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ACRV stock, giving a Buy rating today.

Emily Bodnar’s rating is based on the promising data from Acrivon Therapeutics’ ongoing Phase 2 study of ACR-368 in endometrial cancer. The study has shown a confirmed overall response rate (cORR) of 35% among biomarker-positive patients, which is significantly higher than the typical 10-15% ORR observed with second-line therapies. This suggests a potential for ACR-368 to outperform the standard of care in this patient population.
Furthermore, the safety profile of ACR-368 appears favorable, with no long-lasting myelosuppression or severe liver toxicities reported. Despite the decline in ORR from earlier updates, the results remain encouraging, especially given the severe nature of the patient population involved. These factors together indicate a strong potential for ACR-368 in treating endometrial cancer, justifying the Buy rating.

In another report released today, JMP Securities also maintained a Buy rating on the stock with a $17.00 price target.